drugset / Trial / NCT04742959

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

NCT04742959

Phase 1/2 Completed 203 enrolled TransThera Sciences (Nanjing), Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.

Timeline

Start
2021-03-14
Primary completion
2024-02-20
Completion
2024-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 100 mg/m2 Other
Subject Tinengotinib Small molecule Oral